Sign in or create an account to add this stock to your watchlist.
About Santarus (NASDAQ:SNTS)
Santarus, Inc. (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists. As of December 31, 2012, the Company's marketed and approved products included Uceris (budesonide), Zegerid (omeprazole/sodium bicarbonate), Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) tablets and Fenoglide (fenofibrate) tablets. As of December 31, 2012, the Company's investigational drugs included Ruconest (recombinant human C1 esterase inhibitor), Rifamycin SV MMX, and SAN-300 (anti-VLA-1 antibody). In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:SNTS
CUSIP80281730
Phone+1-858-3145700
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Santarus (NASDAQ:SNTS) Frequently Asked Questions
What is Santarus' stock symbol?
Santarus trades on the NASDAQ under the ticker symbol "SNTS."
Has Santarus been receiving favorable news coverage?
Headlines about SNTS stock have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Santarus earned a news impact score of 0.24 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 45.85 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Santarus?
Shares of SNTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Santarus?
Santarus' mailing address is 3611 Valley Centre Dr Ste 400, SAN DIEGO, CA 92130-3331, United States. The biopharmaceutical company can be reached via phone at +1-858-3145700.
MarketBeat Community Rating for Santarus (SNTS)
MarketBeat's community ratings are surveys of what our community members think about Santarus and other stocks. Vote "Outperform" if you believe SNTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Santarus (NASDAQ:SNTS) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
(Data available from 5/22/2016 forward)
Santarus (NASDAQ:SNTS) Earnings History and Estimates Chart
Santarus (NASDAQ SNTS) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2013 | Q313 | $0.33 | $0.45 | $94.45 million | $98.79 million | View | N/A |  |
| 8/6/2013 | Q2 2013 | $0.18 | $0.94 | $82.90 million | $89.40 million | View | N/A | |
| 5/6/2013 | Q1 2013 | $0.15 | $0.25 | $74.70 million | $79.44 million | View | N/A | |
| 3/4/2013 | Q4 2012 | $0.01 | $0.08 | $62.02 million | $70.20 million | View | N/A | |
| 11/7/2012 | Q312 | $0.10 | $0.13 | $53.04 million | $54.70 million | View | N/A | |
| 8/7/2012 | | $0.08 | $0.05 | | | View | N/A | |
| 5/8/2012 | | ($0.01) | $0.01 | | | View | N/A | |
| 3/5/2012 | Q4 2011 | $0.02 | $0.03 | | | View | N/A | |
| 11/7/2011 | Q3 2011 | $0.01 | $0.01 | | | View | N/A | |
| 8/3/2011 | Q2 2011 | | $0.04 | | | View | N/A | |
| 5/4/2011 | Q1 2011 | ($0.03) | ($0.01) | | | View | N/A | |
| 3/3/2011 | Q4 2010 | ($0.28) | ($0.03) | | | View | N/A | |
| 11/8/2010 | Q3 2010 | ($0.21) | ($0.32) | | | View | N/A | |
| 8/2/2010 | Q2 2010 | $0.04 | $0.10 | | | View | N/A | |
| 5/6/2010 | Q1 2010 | ($0.01) | $0.05 | | | View | N/A | |
| 3/3/2010 | Q4 2009 | $0.20 | $0.40 | | | View | N/A | |
| 11/4/2009 | Q3 2009 | ($0.01) | $0.09 | | | View | N/A | |
| 8/3/2009 | Q2 2009 | ($0.01) | $0.02 | | | View | N/A | |
| 5/6/2009 | Q1 2009 | ($0.05) | $0.02 | | | View | N/A | |
| 3/5/2009 | Q4 2008 | ($0.01) | $0.07 | | | View | N/A | |
| 11/3/2008 | Q3 2008 | ($0.10) | ($0.08) | | | View | N/A | |
| 8/4/2008 | Q2 2008 | ($0.05) | $0.06 | | | View | N/A | |
| 5/7/2008 | Q1 2008 | ($0.16) | ($0.15) | | | View | N/A | |
| 3/3/2008 | Q4 2007 | ($0.26) | ($0.16) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Santarus (NASDAQ:SNTS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Santarus (NASDAQ SNTS) Insider Trading and Institutional Ownership History
Santarus (NASDAQ SNTS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/16/2013 | Gerald Proehl | CEO | Sell | 56,643 | $31.95 | $1,809,743.85 | 30,538 | |
| 12/16/2013 | Kent Snyder | Director | Sell | 7,500 | $31.95 | $239,625.00 | | |
| 12/9/2013 | Meules Julie De | VP | Sell | 15,165 | $31.95 | $484,521.75 | 443 | |
| 11/15/2013 | Kent Snyder | Director | Sell | 7,500 | $32.01 | $240,075.00 | | |
| 11/11/2013 | Meules Julie De | VP | Sell | 15,165 | $31.94 | $484,370.10 | 380 | |
| 10/15/2013 | Gerald Proehl | CEO | Sell | 50,000 | $22.32 | $1,116,000.00 | 30,190 | |
| 10/15/2013 | Kent Snyder | Director | Sell | 7,500 | $22.31 | $167,325.00 | | |
| 10/10/2013 | Debra Crawford | CFO | Sell | 16,614 | $21.90 | $363,846.60 | 166,326 | |
| 10/9/2013 | Meules Julie De | VP | Sell | 15,165 | $21.14 | $320,588.10 | 380 | |
| 10/8/2013 | Maria Bedoya-Toro | SVP | Sell | 10,000 | $21.39 | $213,900.00 | 48,695 | |
| 10/7/2013 | Carey Fox | SVP | Sell | 17,100 | $21.91 | $374,661.00 | 24,567 | |
| 10/1/2013 | William C Denby | VP | Sell | 24,450 | $23.03 | $563,083.50 | | |
| 9/16/2013 | Gerald Proehl | CEO | Sell | 50,000 | $22.19 | $1,109,500.00 | 28,425 | |
| 9/16/2013 | Kent Snyder | Director | Sell | 7,500 | $22.18 | $166,350.00 | | |
| 9/10/2013 | Debra P Crawford | CFO | Sell | 19,000 | $22.38 | $425,220.00 | | |
| 9/9/2013 | Carey J Fox | SVP | Sell | 17,100 | $22.19 | $379,449.00 | | |
| 9/9/2013 | Meules Julie A De | VP | Sell | 15,165 | $21.90 | $332,113.50 | | |
| 9/5/2013 | Michael D Step | SVP | Sell | 30,303 | $23.17 | $702,120.51 | | |
| 9/3/2013 | William Denby | VP | Sell | 24,450 | $22.43 | $548,413.50 | | |
| 8/15/2013 | Kent Snyder | Director | Sell | 7,500 | $25.89 | $194,175.00 | | |
| 8/12/2013 | Debra Crawford | CFO | Sell | 19,000 | $26.40 | $501,600.00 | 166,326 | |
| 8/9/2013 | Meules Julie De | VP | Sell | 15,165 | $26.55 | $402,630.75 | 380 | |
| 8/8/2013 | Maria Bedoya-Toro | SVP | Sell | 10,000 | $27.35 | $273,500.00 | 48,695 | |
| 8/7/2013 | Carey Fox | SVP | Sell | 17,100 | $27.36 | $467,856.00 | 24,567 | |
| 8/2/2013 | E David Ballard II | SVP | Sell | 9,000 | $24.96 | $224,640.00 | | |
| 8/1/2013 | William C Denby | VP | Sell | 24,450 | $24.77 | $605,626.50 | | |
| 7/15/2013 | Kent Snyder | Director | Sell | 35,000 | $25.36 | $887,600.00 | | |
| 7/10/2013 | Debra P Crawford | CFO | Sell | 19,000 | $23.17 | $440,230.00 | | |
| 7/9/2013 | Meules Julie A De | VP | Sell | 15,165 | $23.52 | $356,680.80 | | |
| 7/8/2013 | Maria E Bedoya-Toro | SVP | Sell | 10,000 | $23.34 | $233,400.00 | | |
| 7/5/2013 | Michael D Step | SVP | Sell | 30,301 | $21.76 | $659,349.76 | | |
| 7/3/2013 | Warren E Hall | VP | Sell | 28,749 | $21.54 | $619,253.46 | | |
| 7/2/2013 | E David Ballard II | SVP | Sell | 9,000 | $21.45 | $193,050.00 | | |
| 7/1/2013 | William C Denby | VP | Sell | 25,050 | $21.56 | $540,078.00 | | |
| 6/10/2013 | Debra P Crawford | CFO | Sell | 19,000 | $21.45 | $407,550.00 | | |
| 6/10/2013 | Maria E Bedoya-Toro | SVP | Sell | 10,000 | $21.57 | $215,700.00 | | |
| 6/10/2013 | Meules Julie A De | VP | Sell | 15,165 | $21.67 | $328,625.55 | | |
| 6/7/2013 | Carey J Fox | SVP | Sell | 17,100 | $20.54 | $351,234.00 | | |
| 6/3/2013 | Daniel D Burgess | Director | Sell | 8,000 | $21.34 | $170,720.00 | | |
| 6/3/2013 | E David Ballard II | SVP | Sell | 9,000 | $21.34 | $192,060.00 | | |
| 6/3/2013 | William C Denby | VP | Sell | 24,450 | $21.46 | $524,697.00 | | |
| 5/15/2013 | Cha Alessandro Della | Director | Sell | 16,500 | $21.33 | $351,945.00 | | |
| 5/15/2013 | Technologies Ltd Cosmo | Major Shareholder | Sell | 4,887,500 | $17.68 | $86,411,000.00 | | |
| 5/14/2013 | Michael E Herman | Director | Sell | 25,000 | $20.77 | $519,250.00 | | |
| 5/10/2013 | Debra P Crawford | CFO | Sell | 18,643 | $19.27 | $359,250.61 | | |
| 5/9/2013 | Meules Julie A De | VP | Sell | 15,165 | $20.10 | $304,816.50 | | |
| 5/8/2013 | Maria E Bedoya-Toro | SVP | Sell | 10,000 | $20.53 | $205,300.00 | | |
| 5/1/2013 | Daniel D Burgess | Director | Sell | 8,000 | $17.88 | $143,040.00 | | |
| 5/1/2013 | William C Denby | VP | Sell | 24,450 | $17.90 | $437,655.00 | | |
| 4/10/2013 | Debra P Crawford | CFO | Sell | 19,000 | $16.82 | $319,580.00 | | |
| 12/18/2012 | Ted W Love | Director | Buy | 185,000 | $10.88 | $2,012,800.00 | | |
(Data available from 1/1/2013 forward)
Santarus (NASDAQ SNTS) News Headlines
| Source: |
|
Santarus (NASDAQ:SNTS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Santarus (NASDAQ:SNTS) Income Statement, Balance Sheet and Cash Flow Statement
Santarus (NASDAQ SNTS) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
